We signed exclusive collaboration agreement with Sentinel Oncology in November 2020. Based on the agreement, we will co-develop PEP07, a Chk1 inhibitor, with Sentinel Oncology. The PEP07 treatment can accumulate DNA damage in cells, lead to replication catastrophe, and eventually induce cell apoptosis.
Currently we are optimizing API synthesis complying cGMP and conducting preclinical pharmacological, pharmacokinetic, and GLP toxicological studies. The development goal is to submit IND.